drugset / Trial / NCT05445128
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.
Timeline
- Start
- 2022-06-24
- Primary completion
- 2022-12-08
- Completion
- 2023-02-02
Outcome
Outcome not reported
Stopped (Business): “This study was voluntarily terminated due to a business decision not to proceed, and not due to any safety issue.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MGTA-145 | Protein / enzyme biologic | — | Intravenous |
| Subject | Plerixafor | Small molecule | 240 ug/kg | Subcutaneous |